Maintenance chemotherapy for ovarian cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Mei, Ling ^a   Fang, Fang ^a   Wei, Dong Mei ^a   Chen, Hui ^a   Liu, Guan Jian ^b   Xie, Huan Yu ^a   Wang, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; ELECTRONICS; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; THERAPY EFFECT;

EID: 55049096773     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007414     Document Type: Review

References (14)

1. Bertelsen 1993 Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, et al.A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology 1993;49(1):30-6.
2. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,graphical test. BMJ 1997;315(7109):629-34.
3. Hakes 1992 Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC. Randomized prospective trial of 5 versus 10 cycles of cyclopphosphamide doxorubincin and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology 1992;45(3):284-8.
4. Higgins 2002 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
5. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions 5.0.0 [Updated February 2008] Vol. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
6. Kikuchi 2005 Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opinion on Pharmacotherapy 2005;6(5):743-54.
7. Lambert 1997 Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Annals of Oncology 1997;8:327-33.
8. Markman 2003 Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD. Phase III randomized trial of 12 versus 3months ofmaintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology 2003;21:2460-5.
9. Ozols 2004 Ozols R.F. Maintenance chemotherapy standard care. ASCO. 2004.
10. Ozols 2006 Ozols RF. Challenges for chemotherapy in ovarian cancer. Annals of Oncology 2006;17(suppl.5):181-7.
11. Parmar 1998 Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
12. Stuart 2003 Stuart GCE. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic Oncology 2003;90:8-15.
13. Thigpen 2004 Thigpen T. First-line therapy for ovarian carcinoma: What's next?. Cancer Investigation 2004;22(suppl 2):21-8.
14. Varia 2003 Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:2849-55.